决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Single VHH-directed BCMA CAR-NK cells for multiple myeloma.
这些结果表明,单一 VHH 导向的 BCMA CAR-NK 细胞表现出显著的特异性杀伤能力,使其成为多发性骨髓瘤治疗中免疫治疗的潜在候选。
自然杀伤(NK)细胞是制备“现货型”CAR产品的有前景替代来源,其细胞因子释放综合征(CRS)风险低于CAR-T细胞。我们合成了4种由单个VHH结构域介导靶向的抗BCMA CAR,分别采用不同胞内结构域(2B4或CD28)和铰链结构域(CD28或IgG1),并异位表达IL-15。使用K562-mbIL21饲养细胞在体外扩增外周血(PB)来源NK细胞;随后以BaEV-Rless假病毒包膜慢病毒载体实现稳定CAR转导。异位表达IL-15的BCMA-CD28-IL15 CAR-NK细胞,与缺少IL-15的BCMA-CD28 CAR-NK及具有IgG1铰链结构域的BCMA-hIgG1-IL15 CAR-NK相比,显示出更强细胞毒性。我们还评估了具有2B4胞内结构域的BCMA-2B4-IL15 CAR-NK细胞的细胞毒能力。体外实验中,BCMA-CD28-IL15 CAR-NK对BCMA阳性肿瘤细胞的细胞毒作用更强、细胞因子分泌更多,优于BCMA-2B4-IL15 CAR-NK。在MM.1S-Luc小鼠模型中,BCMA-CD28-IL15 CAR-NK抑制肿瘤细胞生长并延长小鼠生存。这些结果表明,单VHH靶向的BCMA CAR-NK具有显著的特异性杀伤能力,是治疗多发性骨髓瘤的潜在免疫疗法候选。
Natural killer (NK) cells are promising alternatives for the production of "off-the-shelf" CAR products, posing a lower risk of cytokine release syndrome (CRS) than CAR-T cells. We synthesized four single VHH-directed anti-BCMA CARs, incorporating various intracellular regions (2B4 versus CD28) and hinge domains (CD28 versus IgG1) and ectopically producing IL-15. NK cells derived from peripheral blood (PB) were expanded ex vivo by K562-mbIL21 feeder cells. Stable CAR transduction was obtained through lentiviral transduction with the BaEV-Rless pseudotyped lentiviral vector. BCMA-CD28-IL15 CAR-NK cells with ectopic expression of IL-15 exhibited superior cytotoxicity were compared to BCMA-CD28 CAR-NK cells lacking IL-15 and BCMA-hIgG1-IL15 CAR-NK cells with an IgG1 hinge domain. We further assessed the cytotoxic capabilities of BCMA-2B4-IL15 CAR-NK cells with 2B4 intracellular domain. The BCMA-CD28-IL15 CAR-NK cells revealed stronger cytotoxicity and higher cytokine secretion against BCMA + tumor cells than BCMA-2B4-IL15 CAR-NK cells in vitro. In the MM.1S-Luc mouse model, BCMA-CD28-IL15 CAR-NK inhibited the growth of tumor cells and prolonged mouse survival. These results show that the single VHH-directed BCMA CAR-NK cells exhibited remarkable specific killing ability, making them a potential candidate for immunotherapy in multiple myeloma treatment.
MEMBER ACCOUNT
登录成功会直接打开下一页。